GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Cyclically Adjusted PB Ratio

Sarepta Therapeutics (Sarepta Therapeutics) Cyclically Adjusted PB Ratio : 11.93 (As of Jun. 10, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Sarepta Therapeutics's current share price is $123.35. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $10.34. Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is 11.93.

The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

SRPT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.66   Med: 11.59   Max: 38.73
Current: 11.93

During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PB Ratio was 38.73. The lowest was 3.66. And the median was 11.59.

SRPT's Cyclically Adjusted PB Ratio is ranked worse than
91.68% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs SRPT: 11.93

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sarepta Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $10.172. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted PB Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.13 23.15 10.60 13.55 9.55

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.02 11.40 11.98 9.55 12.52

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sarepta Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=123.35/10.34
=11.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=10.172/131.7762*131.7762
=10.172

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.351 100.560 9.633
201409 6.929 100.428 9.092
201412 5.995 99.070 7.974
201503 4.855 99.621 6.422
201506 3.983 100.684 5.213
201509 2.937 100.392 3.855
201512 4.172 99.792 5.509
201603 3.036 100.470 3.982
201606 2.537 101.688 3.288
201609 7.518 101.861 9.726
201612 6.149 101.863 7.955
201703 7.811 102.862 10.007
201706 6.826 103.349 8.704
201709 10.797 104.136 13.663
201712 12.181 104.011 15.433
201803 11.860 105.290 14.844
201806 10.536 106.317 13.059
201809 9.594 106.507 11.870
201812 14.524 105.998 18.056
201903 18.191 107.251 22.351
201906 14.788 108.070 18.032
201909 13.358 108.329 16.249
201912 10.882 108.420 13.226
202003 14.685 108.902 17.770
202006 13.296 108.767 16.109
202009 11.322 109.815 13.586
202012 9.597 109.897 11.508
202103 6.714 111.754 7.917
202106 6.077 114.631 6.986
202109 5.872 115.734 6.686
202112 10.651 117.630 11.932
202203 9.793 121.301 10.639
202206 8.299 125.017 8.748
202209 4.909 125.227 5.166
202212 4.377 125.222 4.606
202303 7.652 127.348 7.918
202306 7.949 128.729 8.137
202309 8.172 129.860 8.293
202312 9.168 129.419 9.335
202403 10.172 131.776 10.172

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (NAS:SRPT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sarepta Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Executives
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901